Clinical Trial Update: Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden [Phase 1]

View source ↗

Summary

Phase 1 safety study of increasing doses of OXi4503 (combretasatin A1 diphosphate) as monotherapy in patients with hepatic tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Metastases

Drugs mentioned

• OXi4503

Snippet

Sponsor: Mateon Therapeutics | Conditions: Neoplasm Metastasis | Phase 1 | Status: COMPLETED